BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420-425. [PMID: 23248248 DOI: 10.1200/jco.2012.44.5924] [Cited by in Crossref: 98] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang T, Fong ZV, Pak L, Wang SJ, Wei J, Wang J. A Modified T-stage Classification for Gastric Neuroendocrine Tumors. J Surg Res 2021;270:486-94. [PMID: 34800795 DOI: 10.1016/j.jss.2021.10.002] [Reference Citation Analysis]
2 Pasquer A, Walter T, Milot L, Hervieu V, Poncet G. Principles of Surgical Management of Small Intestinal NET. Cancers (Basel) 2021;13:5473. [PMID: 34771639 DOI: 10.3390/cancers13215473] [Reference Citation Analysis]
3 Jiang S, Zhao L, Xie C, Su H, Yan Y. Prognostic Performance of Different Lymph Node Staging Systems in Patients With Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:402. [PMID: 32733379 DOI: 10.3389/fendo.2020.00402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Clift AK, Faiz O, Goldin R, Martin J, Wasan H, Liedke MO, Schloericke E, Malczewska A, Rindi G, Kidd M, Modlin IM, Frilling A. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocr Connect 2017;6:71-81. [PMID: 28104724 DOI: 10.1530/EC-16-0114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
5 Maurer E, Heinzel-Gutenbrunner M, Rinke A, Rütz J, Holzer K, Figiel J, Luster M, Bartsch DK. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. J Neuroendocrinol 2021;:e13076. [PMID: 34964186 DOI: 10.1111/jne.13076] [Reference Citation Analysis]
6 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
7 Clancy TE. Liver-directed therapy for neuroendocrine liver metastases. International Journal of Endocrine Oncology 2015;2:75-88. [DOI: 10.2217/ije.14.36] [Reference Citation Analysis]
8 Wright MF, Cates J, Gonzalez RS, Das S, Berlin JD, Shi C. Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. Am J Surg Pathol 2019;43:559-63. [PMID: 30702499 DOI: 10.1097/PAS.0000000000001225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol 2018;79:109-15. [PMID: 29763717 DOI: 10.1016/j.humpath.2018.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
11 Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg 2020;4:652-9. [PMID: 33319155 DOI: 10.1002/ags3.12396] [Reference Citation Analysis]
12 Hendifar AE, Dhall D, Strosberg JR. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist 2019;24:54-61. [PMID: 30104288 DOI: 10.1634/theoncologist.2018-0187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hughes MS, Azoury SC, Assadipour Y, Straughan DM, Trivedi AN, Lim RM, Joy G, Voellinger MT, Tang DM, Venkatesan AM. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery. 2016;159:350-356. [PMID: 26454678 DOI: 10.1016/j.surg.2015.05.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Martin JA, Warner RR, Wisnivesky JP, Kim MK. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. Eur J Cancer. 2017;76:197-204. [PMID: 28334622 DOI: 10.1016/j.ejca.2017.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
15 Chen BB. Artificial intelligence in pancreatic disease. Artif Intell Med Imaging 2020; 1(1): 19-30 [DOI: 10.35711/aimi.v1.i1.19] [Reference Citation Analysis]
16 Chatani PD, Aversa JG, McDonald JD, Khan TM, Keutgen XM, Nilubol N. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery 2021;170:106-13. [PMID: 33814188 DOI: 10.1016/j.surg.2021.01.048] [Reference Citation Analysis]
17 Komaç Ö, Bengi G, Sağol Ö, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. World J Gastrointest Oncol 2019; 11(2): 139-152 [PMID: 30788040 DOI: 10.4251/wjgo.v11.i2.139] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bilski M, Mertowska P, Mertowski S, Sawicki M, Hymos A, Niedźwiedzka-Rystwej P, Grywalska E. The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers (Basel) 2021;14:177. [PMID: 35008341 DOI: 10.3390/cancers14010177] [Reference Citation Analysis]
19 Kim MK, Warner RR, Ward SC, Harpaz N, Roayaie S, Schwartz ME, Itzkowitz S, Wisnivesky J. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology 2015;101:58-65. [PMID: 25572143 DOI: 10.1159/000371807] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
20 Fata CR, Gonzalez RS, Liu E, Cates JM, Shi C. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. Am J Surg Pathol 2017;41:128-33. [PMID: 27684993 DOI: 10.1097/PAS.0000000000000751] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
21 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192. [PMID: 24699927 DOI: 10.1007/s12022-014-9313-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
22 Sei Y, Zhao X, Forbes J, Szymczak S, Li Q, Trivedi A, Voellinger M, Joy G, Feng J, Whatley M, Jones MS, Harper UL, Marx SJ, Venkatesan AM, Chandrasekharappa SC, Raffeld M, Quezado MM, Louie A, Chen CC, Lim RM, Agarwala R, Schäffer AA, Hughes MS, Bailey-Wilson JE, Wank SA. A Hereditary Form of Small Intestinal Carcinoid Associated With a Germline Mutation in Inositol Polyphosphate Multikinase. Gastroenterology 2015;149:67-78. [PMID: 25865046 DOI: 10.1053/j.gastro.2015.04.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
23 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
24 Frankel AE, Yip WC, Naik E, Hasselbalch HC. Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus. Clin Case Rep 2021;9:e04218. [PMID: 34136234 DOI: 10.1002/ccr3.4218] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Feng LH, Su T, Lu Y, Ren S, Huang L, Qin X, Liao T. A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery. Scand J Gastroenterol 2022;:1-8. [PMID: 35001789 DOI: 10.1080/00365521.2021.2024247] [Reference Citation Analysis]
26 Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, Chung DC, Wang L. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8:4935-4947. [PMID: 27903960 DOI: 10.18632/oncotarget.13632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
27 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
28 Kim MK, Warner RR, Roayaie S, Harpaz N, Ward SC, Itzkowitz S, Wisnivesky JP. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol 2013;31:3776-81. [PMID: 24043726 DOI: 10.1200/JCO.2013.51.1477] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
29 Xie JB, Pang YS, Li X, Wu XT. Role of Removed Lymph Nodes on the Prognosis of M0 Small-Bowel Neuroendocrine Tumors: a Propensity Score Matching Analysis from SEER Database. J Gastrointest Surg 2021. [PMID: 34109533 DOI: 10.1007/s11605-021-04994-3] [Reference Citation Analysis]
30 Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017;46:707-714. [PMID: 28609356 DOI: 10.1097/mpa.0000000000000850] [Cited by in Crossref: 124] [Cited by in F6Publishing: 57] [Article Influence: 31.0] [Reference Citation Analysis]
31 Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B, Nordvall D, Janson ET. Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2. Endocrine 2021;72:893-904. [PMID: 33244704 DOI: 10.1007/s12020-020-02534-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015;5:119-76. [PMID: 26854147 DOI: 10.3390/diagnostics5020119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
33 Kleiman DA, Beninato T, Sultan S, Crowley MJ, Finnerty B, Kumar R, Panarelli NC, Liu YF, Lieberman MD, Seandel M. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann Surg Oncol. 2014;21 Suppl 4:S672-S679. [PMID: 24854489 DOI: 10.1245/s10434-014-3787-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
34 Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125-35. [PMID: 28076709 DOI: 10.1056/NEJMoa1607427] [Cited by in Crossref: 1120] [Cited by in F6Publishing: 537] [Article Influence: 224.0] [Reference Citation Analysis]
35 Ren S, Wang Z. Letter regarding "Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase". Abdom Radiol (NY) 2021;46:1648-9. [PMID: 33074427 DOI: 10.1007/s00261-020-02793-z] [Reference Citation Analysis]
36 Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. Curr Treat Options Oncol 2018;19:69. [PMID: 30397729 DOI: 10.1007/s11864-018-0592-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Chen L, Zhou L, Zhang M, Shang L, Zhang P, Wang W, Fang C, Li J, Xu T, Tan H, Zhang P, Qiu M, Yu X, Jin K, Chen Y, Chen H, Lin R, Zhang Q, Shen L, Chen M, Li J, Li L, Chen J. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. BMC Cancer 2017;17:521. [PMID: 28778195 DOI: 10.1186/s12885-017-3490-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
38 Gajate P, Alonso-Gordoa T, Martínez-Sáez O, Molina-Cerrillo J, Grande E. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. Clin Transl Oncol 2018;20:561-9. [PMID: 29124519 DOI: 10.1007/s12094-017-1758-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
39 Lee SH, Lee TH, Jang SH, Choi CY, Lee WM, Min JH, Cho HD, Park SH. Ampullary neuroendocrine tumor diagnosed by endoscopic papillectomy in previously confirmed ampullary adenoma. World J Gastroenterol 2016; 22(13): 3687-3692 [PMID: 27053861 DOI: 10.3748/wjg.v22.i13.3687] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2021;11:681149. [PMID: 34109127 DOI: 10.3389/fonc.2021.681149] [Reference Citation Analysis]
41 Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol 2017;18:14. [PMID: 28286921 DOI: 10.1007/s11864-017-0461-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
42 Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018;472:341-9. [PMID: 29134440 DOI: 10.1007/s00428-017-2258-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
43 Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D, Pellegrinelli A, Milione M, Ferrero S. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. Endocrine 2017;58:360-7. [PMID: 28210937 DOI: 10.1007/s12020-017-1249-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]